ZSP1601,a pan-PDE inhibitor for MASH Raw data

This study aims to investigate the therapeutic effects and mechanism of action of ZSP1601, a novel non-specific phosphodiesterase small molecule inhibitor, in improving metabolic dysfunction-associated steatohepatitis (MASH). ZSP1601 was developed through structural modification and optimization based on the chemical framework of Pentoxifylline. It inhibits PDE activity, thereby elevating cyclic adenosine monophosphate levels and suppressing the transcription of tumor necrosis factor-alpha (TNF-α) gene, which may confer beneficial effects in the treatment of MASH. The research confirms the efficacy and mechanistic basis of ZSP1601 as a non-specific PDE small molecule inhibitor against MASH. The compound was identified as a non-specific PDE inhibitor through integrated approaches including chemical structure design, synthesis, molecular docking simulations, and in vitro enzymatic assays. Subsequent in vitro and in vivo pharmacodynamic models were employed to evaluate the therapeutic potential of ZSP1601 in MASH. Furthermore, pharmacokinetic studies demonstrated that ZSP1601 exhibits favorable pharmacokinetic properties suitable for oral administration. By combining medicinal chemistry design, chemical synthesis, pharmacological evaluation models, and pharmacokinetic analyses, this study elucidates the underlying mechanisms of ZSP1601 in ameliorating MASH and assesses its druggability. ZSP1601 significantly improved the NAS score and reduced liver fibrosis in MASH model animals by lowering TNF-α levels, exhibiting superior efficacy compared to the positive control compound Pentoxifylline. The development of ZSP1601 offers a novel therapeutic strategy for the treatment of MASH. Given its potential, ZSP1601 is currently being studied in phase II clinical trials.